CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Burning Rock Biotech Ltd (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Burning Rock Biotech Ltd (ADR)
No. 5 Xingdao Ring Road North
International Bio Island
Phone: +86 18501641666p:+86 18501641666 GUANGZHOU, GNG  510005  China Ticker: BNRBNR
Business Summary
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2022YesYes---

Industries
SIC Code Description
8071 Medical laboratories
2835 In vitro and in vivo diagnostic substances
5047 Medical, dental, and hospital equipment and supplies
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Founder YanshengHan 44
Chief Financial Officer, Director LeoLi 38 1/1/2020 1/1/2019
Chief Technology Officer, Director ZhihongZhang 47 6/30/2023 3/1/2016
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Beijing Burning Rock Biotech Limited
BNR
BR Hong Kong Limited
Burning Rock Biotechnology (Shanghai) Co., Ltd.
Burning Rock Dx LLC

General Information
Number of Employees: 1,138 (As of 12/31/2022)
Outstanding Shares: 102,675,392 (As of 12/31/2023)
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024